Cepheid Nabs First FDA Authorization For Rapid-Response COVID-19 Test

Point-of-care test can give results in 45 minutes

A rapid-response test from Danaher business unit Cepheid will be the first quick COVID-19 diagnostic to reach the US market, the US FDA announced on 21 March.

microbiologist with a tube of biological sample contaminated by Coronavirus with label Covid-19 / doctor in the laboratory with a biological tube for analysis and sampling of Covid-19 infectious disea

A newly authorized point-of-care diagnostic could cut the wait for a COVID-19 diagnosis from days to hours, the US Food and Drug Administration announced on 21 March.

The Xpert Xpress SARS-CoV-2 test, developed by Danaher Corp. business unit Cepheid, uses samples collected via a nasal swab or nasal wash, and offers results in as little as...

More from Regulation

More from Policy & Regulation